Endovascular Therapy Versus Anticoagulation for Treatment of Cerebral Venous Sinus Thrombosis
Neurologist 27:69-73, Xu, Z.,et al, 2022
Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients with Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke
Stroke 49:2237-2240, Jin, C.,et al, 2018
Intravenous Thrombolysis in Acute Ischemic Stroke Patients Pretreated with Non-Vitamin K Antagonist Oral Anticoagulants
Stroke 48:2031-2033, Tsivgoulis, G. & Safouris, A., 2017
Stroke Outcomes with use of Antithrombotics within 24 hours after Recanalization Treatment
Neurol 87:996-1002, Jeong, H.G.,et al, 2016
Rethinking Warfarin for Atrial Fibrillation
JAMA 311:1246, Zuccott, G & Pflomm, J.M., 2014
Factor Xa Inhibitors vs Warfarin for Preventing Stroke and Thromboembolism in Patients with Atrial Fibrillation
JAMA 311:1150-1151, Bruins Slot, K.M.H. & Berge, E., 2014
New Antithrombotic Drugs for Atrial Fibrillation: Caution is Needed
Lancet 379:e24, Bell,S.,et al, 2012
Self-Monitoring of Oral Anticoagulation: Systematic Review and Meta-Analysis of Individual Patient Data
Lancet 379:322-34, Heneghan,C., 2012
Anticoagulation for Cerebral Venous Sinus Thrombosis
Stroke 43:e41-e42, Coutinho,J.M.,et al, 2012
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data
Pharmacol Ther 129:185-194, Terry, K.W.,et al, 2011
Cerebral Venous Sinus Thrombosis Associated with Cerebral Hemorrhage Is Anticoagulant Treatment Safe?
The Neurologist 17:208-210, Fuentes, B.,et al, 2011
Dabigatran Challenges Warfarins Superiority for Stroke Prevention in Atrial Fibrillation
Stroke 41:1307-1309, Schwartz,N.E. &Albers,G.W., 2010
Quality of Anticoagulation Control in Atrial Fibrillation
Lancet 376:935-937, Lane,D.A. &Lip,G.Y.H., 2010
Effect of Home Testing of International Normalized Ratio on Clinical Events
NEJM 363:1608-1620, Matchar,D.B.,et al, 2010
Study Design of the CLOSURE I Trial: A Prospective, Multicenter, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex Septal Closure System Versus Best Medical Therapy in Patients With Stroke or TIA Due to Presumed Paradoxical Embolism Through a PFO
Stroke 41:2872-2883, Furlan,A.J.,et al, 2010
Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention? No
Stroke 40:1944-1945,1946, Fisher,M., 2009
Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk: The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W)
Stroke 39:1482-1486,1406, Healey,J.S.,et al, 2008
Anticoagulation After Cardioembolic Stroke: To Bridge or Not to Bridge
Arch Neurol 65:1169-1173,1157, Hallevi,H.,et al., 2008
The Increasing Incidence of Anticoagulant-Associated Intracerebral Hemorrhage
Neurol 68:116-121, Flaherty,M.L.,et al, 2007
Efficacy and Safety of Anticoagulant Treatment in Acute Cardioembolic Stroke: A Meta-Analysis of Randomized Controlled Trials
Stroke 38:423-430, Paciaroni,M.,et al, 2007
Secondary Stroke Prevention With Ximelagatran Versus Warfarin in Patients With Atrial Fibrillation: Pooled Analysis of SPORTIF III and V Clinical Trials
Stroke 38:874-880, Akins,P.T.,et al, 2007
Combining Aspirin With Oral Anticoagulant Therapy: Is This a Safe and Effective Practice in Patients With Atrial Fibrillation?
Stroke 38:1652-1654, Gorelick,P.B., 2007
Prognosis and Safety of Anticoagulation in Intracranial Artery Dissection in Adults
Stroke 38:1837-1842, Metso,T.M.,et al, 2007
Comparison of Warfarin and Aspirin for Symptomatic Intracranial Arterial Stenosis
NEJM 352:1305-1316, 1368, Chimowitz,M.I.,et al, 2005
Ximelagatran vs Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation
JAMA 293:690-698,736, SPORTIF Executive Steering Committee for the SPORTIF V Investigators, 2005
Antithrombotic Drugs for Carotid Artery Dissection
Stroke 25:613-614, Lyrer,P.&Engelter,S., 2004
Systematic Review of Long Term Anticoagulation or Antiplatelet Treatment in Patients with Non-rheumatic Atrial Fibrillation
BMJ 322:321-326, Taylor,F.C.,et al, 2001
Tinzaparin in Acute Ischaemic Stroke (TAIST):A Randomised Aspirin-Controlled Trial
Lancet 358:702-710,683, Bath,P.M.W.,et al, 2001
Oral Anticoagulation for Cerebral Ischemic of Arterial Origin
Neurol 57:1993-1999, Torn,M.,et al, 2001
Safety of Discontinuation of Anticoagulation in Patients with Intracranial Hemorrhage at High Thromboembolic Risk
Arch Neurol 57:1710-1713,1682, Phan,T.G.,et al, 2000
Frequency of Major Complications of Aspirin,Warfarin,and Intravenous Heparin for Secondary Stroke Prevention,A Population-Based Study
Ann Int Med 130:14-22, Petty,G.W.,et al, 1999
Low Molecular Wt Heparinoid
ORG 10172 (Danaparoid) , & Outcome After Acute Ischemic Stroke, 10172 Acute Stroke Trtm (TOAST) Inve, t, JAMA 1272,1304,1998., 1998
Comparison of an Anticoagulation Clinic With Usual Medical Care: Anticoagulation Control, Patient Outcomes, and Health Care Costs
Arch Int Med 158:1641-1647, Chiquette,E.,et al, 1998
A Randomized Trial of Anticoagulants Vs Aspirin After Cerebral Ischemia of Presumed Arterial Origin
SPIRIT Study Group, Ann Neurol 42:857-8651997., , 1997
Anticoagulant Treatment as a Risk Factor for Primary Intracerebral Hemorrhage
JNNP 55:1121-1124, Fogelholm,R.,et al, 1992